Existing copper-chelating agents (e.g., trientine, tetrathiomolybdate), originally approved for Wilson’s disease, are now being repurposed to lower systemic copper and upregulate hCTR1, thereby sensitizing resistant tumors to platinum-based chemotherapies [38,109,146,233,234,246,247,248]. Here, SLC31A1 is linked to Wilson disease.